Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TNYA Stock Forecast 2026-2027
$0.76
Current Price
$163.89M
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to TNYA Price Targets
+5,184.0%
To High Target of $40.00
+296.3%
To Median Target of $3.00
+164.2%
To Low Target of $2.00
TNYA Price Momentum
-1.3%
1 Week Change
-5.0%
1 Month Change
-48.3%
1 Year Change
+7.0%
Year-to-Date Change
-67.8%
From 52W High of $2.35
+110.3%
From 52W Low of $0.36
📊 TOP ANALYST CALLS
Did TNYA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Tenaya is one of their latest high-conviction picks.
Latest TNYA Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, TNYA has a bullish consensus with a median price target of $3.00 (ranging from $2.00 to $40.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $0.76, the median forecast implies a 296.3% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TNYA Analyst Ratings
8
Buy
0
Hold
0
Sell
TNYA Price Target Range
Low
$2.00
Average
$3.00
High
$40.00
Current: $0.76
Latest TNYA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TNYA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 18, 2025 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $5.00 |
| Dec 12, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $3.00 |
| Dec 12, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $8.00 |
| Nov 10, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $9.00 |
| Sep 2, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $5.00 |
| Aug 27, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $5.00 |
| Aug 7, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $9.00 |
| May 9, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $9.00 |
| Apr 25, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $5.00 |
| Mar 31, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $5.00 |
| Mar 13, 2025 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $6.00 |
| Mar 12, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $9.00 |
| Mar 12, 2025 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $5.00 |
| Mar 11, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $5.00 |
| Feb 3, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $18.00 |
| Jan 14, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $18.00 |
| Dec 18, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $18.00 |
| Dec 18, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $18.00 |
| Nov 26, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $18.00 |
| Nov 25, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $18.00 |
Tenaya Therapeutics, Inc. (TNYA) Competitors
The following stocks are similar to Tenaya based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TNYA
Tenaya Therapeutics
mkt cap
165.63M
Tenaya Therapeutics, Inc. (TNYA) Financial Data
Tenaya Therapeutics, Inc. has a market capitalization of $163.89M with a P/E ratio of -0.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -96.4%.
Valuation Metrics
Market Cap
$163.89M
Enterprise Value
$77.96M
P/E Ratio
-0.6x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+44.6%
Current Ratio
4.6x
Debt/Equity
13.9x
ROE
-96.4%
ROA
-49.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Tenaya Therapeutics, Inc. (TNYA) Business Model
About Tenaya Therapeutics, Inc.
What They Do
Develops novel therapies for heart disease.
Business Model
Tenaya Therapeutics generates revenue through the research and development of targeted gene therapies and precision medicine techniques aimed at treating heart disease. By addressing the underlying causes of cardiovascular conditions, the company seeks to create transformative treatments that can significantly improve patient outcomes.
Additional Information
Located in South San Francisco, Tenaya Therapeutics emphasizes innovation in the biopharmaceutical sector, focusing on unmet medical needs in cardiovascular health. The company is pioneering platforms for enhancing cardiac muscle function and preventing disease progression, contributing to advancements in regenerative medicine and personalized healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
97
CEO
Mr. Faraz Ali M.B.A.
Country
United States
IPO Year
2021
Website
www.tenayatherapeutics.comTenaya Therapeutics, Inc. (TNYA) Latest News & Analysis
Latest News
Quick Summary
A company plans to release longer-term follow-up data in early 2026 for cohorts from the MyPEAK™-1 trial, which showed positive interim results for TN-201 in adults with MYBPC3-associated HCM.
Why It Matters
Positive interim results for TN-201 indicate potential for future growth and profitability, influencing stock performance and investor confidence in the company’s pipeline for HCM treatment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) shares are down on Friday, trading at 42.39 million volumes, significantly higher than the average of 3.51 million.
Why It Matters
Increased trading volume indicates heightened investor interest or concern, suggesting potential volatility or significant news affecting Tenaya Therapeutics' stock performance.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
Tenaya Therapeutics, Inc. (Nasdaq: TNYA) announced a public offering of 50 million units, aiming to raise $60 million before expenses, to fund its heart disease therapies.
Why It Matters
Tenaya Therapeutics’ public offering raises $60 million, indicating financial growth potential. It may impact stock valuation and investor sentiment regarding the company's future developments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Tenaya Therapeutics (TNYA) presented initial data from the RIDGE-1 Phase Ib/II trial for its TN-401 gene therapy targeting arrhythmogenic right ventricular cardiomyopathy (ARVC).
Why It Matters
Positive data from Tenaya's TN-401 gene therapy trial could indicate potential market approval, impacting stock performance and investor sentiment in biotech.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Tenaya has agreed on amendments to the MyPEAK-1 protocol with the FDA and is implementing these changes at clinical sites.
Why It Matters
FDA agreement on MyPEAK-1 protocol amendments suggests regulatory progress for Tenaya, potentially boosting investor confidence and impacting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Tenaya Therapeutics plans to offer units of common stock and warrants to investors, including pre-funded units. The offering's completion and terms are subject to market conditions.
Why It Matters
Tenaya Therapeutics' planned stock offering can dilute existing shares and indicates potential cash needs for development, impacting stock value and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About TNYA Stock
What is Tenaya Therapeutics, Inc.'s (TNYA) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Tenaya Therapeutics, Inc. (TNYA) has a median price target of $3.00. The highest price target is $40.00 and the lowest is $2.00.
Is TNYA stock a good investment in 2026?
According to current analyst ratings, TNYA has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.76. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TNYA stock?
Wall Street analysts predict TNYA stock could reach $3.00 in the next 12 months. This represents a 296.3% increase from the current price of $0.76. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tenaya Therapeutics, Inc.'s business model?
Tenaya Therapeutics generates revenue through the research and development of targeted gene therapies and precision medicine techniques aimed at treating heart disease. By addressing the underlying causes of cardiovascular conditions, the company seeks to create transformative treatments that can significantly improve patient outcomes.
What is the highest forecasted price for TNYA Tenaya Therapeutics, Inc.?
The highest price target for TNYA is $40.00 from at , which represents a 5,184.0% increase from the current price of $0.76.
What is the lowest forecasted price for TNYA Tenaya Therapeutics, Inc.?
The lowest price target for TNYA is $2.00 from at , which represents a 164.2% increase from the current price of $0.76.
What is the overall TNYA consensus from analysts for Tenaya Therapeutics, Inc.?
The overall analyst consensus for TNYA is bullish. Out of 8 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are TNYA stock price projections?
Stock price projections, including those for Tenaya Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 4:38 AM UTC